Revenue for the quarter totaled $6.7, exceeding Wall Street estimates of $6.56 billion, as compiled by Refinitiv.

Adjusted earnings per share increased to $4.70 from $4.08 a year earlier, beating analyst estimates of $4.42.

Net income rose 14% to $2.14 billion.

For the full year, Amgen narrowed its outlook for adjusted earnings per share to a range of $17.25 to $17.85 on revenue of $26 billion to $26.3 billion, from its previous forecast of $17 to $18 per share on revenue of $25.5 billion to $26.4 billion.

(Reporting By Deena Beasley; Editing by Bill Berkrot)

By Deena Beasley